Iqvia price target lowered to $216 from $263 at Truist

Truist analyst Jailendra Singh lowered the firm’s price target on Iqvia (IQV) to $216 from $263 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results for Contract Research Organizations, or CROs. The firm is lowering its estimates and price targets for to reflect recent trends and macro uncertainty. Truist states it had previously believed that large pharma market was already halfway through with respect to portfolio reprioritization, but given the funding trends of the past two months and the uncertain pharma industry environment in general, its baseline assumption now sees biotech recovery being pushed out to at least the second half of 2025 and the large pharma market recovery to the first half of 2026, the analyst tells investors in a research note.